Search research articles
Contact Us
Filters
Showing results (71-80 of 119) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2008
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
Martin Jädersten, Luca Malcovati, Ingunn Dybedal, et al.
Leukemia & Lymphoma
|
October 6, 2007
Three-dimensional culturing of the Hodgkin lymphoma cell-line L1236 induces a HL tissue-like gene expression pattern
Anna Birgersdotter, Karl R N Baumforth, Anna Porwit, et al.
British Journal of Haematology
|
March 9, 2021
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
Joana M Rodrigues, Anna Nikkarinen, Peter Hollander, et al.
Annals of Hematology
|
January 10, 2021
Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome
Dolores Subirá, Canan Alhan, Uta Oelschlaegel, et al.
Haematologica
|
December 15, 2022
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors
Anna Sandström Gerdtsson, Joana de Matos Rodrigues, Christian Winther Eskelund, et al.
American Journal of Clinical Pathology
|
October 1, 2016
Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group
Lambert Busque, Anna Porwit, Radmila Day, et al.
American Journal of Epidemiology
|
September 30, 2005
Medication use and risk of non-Hodgkin's lymphoma
Ellen T Chang, Karin Ekström Smedby, Henrik Hjalgrim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2011
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
Martin Jädersten, Leonie Saft, Alexander Smith, et al.
Journal of the National Cancer Institute
|
January 5, 2006
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype
Karin Ekström Smedby, Henrik Hjalgrim, Johan Askling, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 5, 2015
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group
Shireen Sirhan, Lambert Busque, Lynda Foltz, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 119) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 19, 2008
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
Martin Jädersten, Luca Malcovati, Ingunn Dybedal, et al.
Leukemia & Lymphoma
|
October 6, 2007
Three-dimensional culturing of the Hodgkin lymphoma cell-line L1236 induces a HL tissue-like gene expression pattern
Anna Birgersdotter, Karl R N Baumforth, Anna Porwit, et al.
British Journal of Haematology
|
March 9, 2021
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
Joana M Rodrigues, Anna Nikkarinen, Peter Hollander, et al.
Annals of Hematology
|
January 10, 2021
Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome
Dolores Subirá, Canan Alhan, Uta Oelschlaegel, et al.
Haematologica
|
December 15, 2022
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors
Anna Sandström Gerdtsson, Joana de Matos Rodrigues, Christian Winther Eskelund, et al.
American Journal of Clinical Pathology
|
October 1, 2016
Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group
Lambert Busque, Anna Porwit, Radmila Day, et al.
American Journal of Epidemiology
|
September 30, 2005
Medication use and risk of non-Hodgkin's lymphoma
Ellen T Chang, Karin Ekström Smedby, Henrik Hjalgrim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2011
TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression
Martin Jädersten, Leonie Saft, Alexander Smith, et al.
Journal of the National Cancer Institute
|
January 5, 2006
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype
Karin Ekström Smedby, Henrik Hjalgrim, Johan Askling, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 5, 2015
Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group
Shireen Sirhan, Lambert Busque, Lynda Foltz, et al.
Page
of 12